Patient with metastatic renal cell carcinoma treated successfully with pazopanib for four years.
Journal Title: OncoReview - Year 2015, Vol 5, Issue 3
Abstract
We present a case of a patient with metastatic renal cell carcinoma who was treated with pazopanib in the first-line treatment. Although nephrectomy was not performed, there was a positive reaction to the therapy with multi targeted tyrosine kinase inhibitor. After 18 months of the palliative treatment, the cancerous kidney was surgically removed and pazopanib was restarted with the effect of further disease remission. The development of hypertension, complete hair discoloration and isolated hyperbilirubinemia occurred, and there was occasionally hypokalaemia in laboratory findings within 48 months of therapy. No serious adverse events were reported.
Authors and Affiliations
Agnieszka Słowik, Joanna Streb, Robert Chrzan, Krzysztof Krzemieniecki
Keywords
Related Articles
- EP ID EP78720
- DOI 10.5604/20828691.1171780
- Views 220
- Downloads 0
Adriamycin cardiomyopathy with congestive heart failure, cardiogenic shock and emergency heart transplant: 30-year follow up
Doxorubicin chemotherapeutic agent is widely utilized for many types of cancers since the late 1960s. Cardiomyopathy is a well-known side effect of doxorubicin often limiting its use. In many cases doxorubicin cardiomyop...
Myeloma and amyloid
Pleural effusion in patient with chronic myeloid leukemia treated with dasatinib - a case report
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with inherence of a cytogenetic abnormalities in the shape of translocation of gene ABL from chromosome 9 to chromosome 22, t(9,22)(q34;q11). Current standa...
Original vs generic drugs in treatment of chronic myeloid leukaemia
The beginning of the twenty-first century saw a breakthrough in haematology, oncology and general medicine driven by the introduction of imatinib (Glivec) to the treatment of chronic myeloid leukaemia. For the first time...
Sequential oncological therapy and delays in oncological diagnostics and treatment
One of the causes behind the low recovery rate among oncological patients is late diagnosis and delayed treatment. To a large extent it stems from the limited access to standard diagnostic methods, and from the extended...